Get the latest Science News and Discoveries
Eplontersen trial did not meet its primary endpoint in transthyretin-mediated amyloid cardiomyopathy
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
None
Or read this on Eureka Alert